Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

Abstract Background MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials. Immunogenicity of MYL-1501D and reference insulin glargine was examined in both studies. Methods INST...

Full description

Bibliographic Details
Main Authors: Bin Sun, Nilanjan Sengupta, Anita Rao, Charles Donnelly, Vinit Waichale, Arnab Sinha Roy, Shilpa Ramaswamy, Divya Pathak, Ronald R. Bowsher, Yaron Raiter, Patrick Aubonnet, Abhijit Barve
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Endocrine Disorders
Subjects:
Biosimilar
Diabetes mellitus
Immunogenicity
Insulin glargine
MYL-1501D
Online Access:https://doi.org/10.1186/s12902-021-00797-4

Internet

https://doi.org/10.1186/s12902-021-00797-4

Similar Items